|Tested species reactivity||Human|
|Host / Isotype||Mouse / IgG1, kappa|
|Immunogen||Synthetic peptide corresponding to residues 17-35 of human TRAIL.|
|Storage buffer||PBS with 0.05% BSA|
|Contains||0.05% sodium azide|
|Storage Conditions||Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||5 µg/ml|
|Western Blot (WB)||1-2 µg/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
This peptide sequence has been shown to be involved in TRaIL and DR5 (TRaIL-R2) interaction.
Suggested positive control: Jurkat whole cell lysate.
Apoptosis, or programmed cell death, occurs during normal cellular differentiation and development of multicellular organisms. Apoptosis is induced by certain cytokines including TNF and Fas ligand in the TNF family through their death domain containing receptors, TNFR1 and Fas. A novel member in the TNF family was recently identified and designated TRAIL (for TNF-related apoptosis-inducing ligand) and Apo-2L (for Apo-2 ligand) (6,7). TRAIL is a type II membrane protein and expressed in a variety of human tissues. Two novel death domain containing receptors DR4 and DR5 have been identified as the receptor for TRAIL3-6. Like TNF and Fas ligand, TRAIL induces apoptosis and NF-kB activation in many tissues and cells.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.